Neuron23’s NEU-411 Trial Shifts the Parkinson’s Paradigm Toward Precision
Neuron23 advances NEU-411 into Phase II Parkinson’s trial, driven by biomarker-based strategies and strong investor support.
Phase II
Neuron23 advances NEU-411 into Phase II Parkinson’s trial, driven by biomarker-based strategies and strong investor support.